Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for evaluating breast carcinoma chemotherapeutic effect based on seroglycoid glycoform and application thereof

A breast cancer, glycoprotein technology, applied in the field of breast cancer chemotherapy effect markers, can solve the problems of inapplicability to all patients and tumor heterogeneity

Active Publication Date: 2020-06-02
深圳格道糖生物技术有限公司
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] For a long time, tissue biopsy technology has often been used as the gold standard for tumor diagnosis. With the in-depth study of tumors, it has been found that tissue biopsy technology still has limitations such as tumor heterogeneity and not being suitable for all patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for evaluating breast carcinoma chemotherapeutic effect based on seroglycoid glycoform and application thereof
  • Marker for evaluating breast carcinoma chemotherapeutic effect based on seroglycoid glycoform and application thereof
  • Marker for evaluating breast carcinoma chemotherapeutic effect based on seroglycoid glycoform and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] The present invention will be further described by the specific examples given below, but not as a limitation of the present invention.

[0034] In the present invention, 37 lectins (as shown in Table 1) are used to screen lectin probes for detecting the curative effect of chemotherapy for female breast cancer.

[0035] Table 1 Abbreviation comparison table

[0036]

[0037]

[0038] The reagent material used among the present invention comprises: protease inhibitor, dimethyl sulfoxide (DMSO), Cy3, fluorescent dye, Sephadexg G-25 column, bovine serum albumin (BSA), glass sheet base, oxygen silane reagent ( GPTS), Bradford reagent, Tween-20, and commonly used reagents of domestic analytical grade.

[0039] The equipment used includes: ultra-fast refrigerated centrifuge 5804R: Eppendorf, Germany; micronucleic acid and protein analyzer: Implen, Germany; chip spotting instrument: Boao Jingxin SmartArrayer48 spotting instrument; biochip scanner 4000B: Axon, USA; chip ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a marker for evaluating breast carcinoma chemotherapeutic effect based on seroglycoid glycoform and an application of the marker. By detecting an expression level of a sugar chain identified by any one or any combination of lectin LCA, GSL-II, GSL-I, PHA-E+L, WFA and RCA120, whether chemotherapy has a curative effect on a patient subjected to breast cancer chemotherapy or not can be evaluated. The specific basis can be referred to as follows: down regulation is performed on the GSL-II, and a down-regulated Fold-change value is between 0.5 and 1.9; the LCA, the GSL-I andthe RCA120 are up-regulated, and an up-regulated Fold-change value is between 1.68 and 2.4, between 3 and 12.5, and between 0.67 and 2.61; and if PHA-E+L and WFA have no significant difference from ahealthy female control group, then the situation indicates that a curative effect is achieved.

Description

technical field [0001] The invention relates to a breast cancer chemotherapy effect marker based on detection of serum glycoprotein glycoforms and application thereof. Background technique [0002] Breast cancer is the most common malignancy in women and the leading cause of cancer death in women, and worldwide, its incidence and mortality are expected to increase significantly in the next 5 to 10 years. The high incidence of breast cancer seriously endangers women's health. According to the statistics of the latest few years, the overall incidence and mortality of breast cancer in Chinese women are on the rise. At the same time, breast cancer patients are becoming younger and their mortality is increasing. Treatment for breast cancer typically involves surgery, chemotherapy, radiation therapy, endocrine therapy, and targeted therapy. Neoadjuvant chemotherapy has become one of the best options for the treatment of breast cancer, which can improve the quality of life of pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574
CPCG01N33/57415G01N33/57488G01N2333/4724
Inventor 李铮侯瑶
Owner 深圳格道糖生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com